<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081011</url>
  </required_header>
  <id_info>
    <org_study_id>58276</org_study_id>
    <nct_id>NCT05081011</nct_id>
  </id_info>
  <brief_title>Managing Insulin With a Voice AI</brief_title>
  <acronym>MIVA</acronym>
  <official_title>Using an AI-based Voice Assistant to Manage Insulin in Diabetes: a Randomized-Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study randomizes participants to have their basal insulin titrated either through&#xD;
      standard of care or by receiving prompts through interactions with an AI-enabled smart&#xD;
      speaker device. The primary objective of this study is to investigate the feasibility of an&#xD;
      AI-enabled smart speaker device and whether such a device facilitates insulin titration&#xD;
      management, increases insulin adherence and decreases time to optimal insulin dose. The&#xD;
      secondary objective of the study is to explore whether the device improves glycemic control&#xD;
      as defined by improvements in fasting blood sugar.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">June 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 27, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Optimal Insulin Dose</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of days between study start date and goal fasting sugar</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Medication Adherence</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of days adherent to insulin based on logs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attitudes toward Diabetes</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change in Composite Score of Attitudes Toward Diabetes (PAID-5)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attitudes toward Health Technology</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change in Composite Score of Attitudes Toward Health Technology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attitudes Toward Medication Adherence</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change in Composite Score of Attitudes Toward Medication Adherence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic Control</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of fasting sugar within goal at end of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Improvement</measure>
    <time_frame>Day 3 and 8 weeks (assessed at the end of each 3 day period)</time_frame>
    <description>Change in 3-day average fasting sugars between first 3 days and last 3 days of study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Medication Adherence</condition>
  <arm_group>
    <arm_group_label>Voice Assistant Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects have their insulin titrated by a voice assistant device for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects have their insulin titrated via standard of care for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Voice Assistant Device</intervention_name>
    <description>Voice AI-enabled smart speaker device delivers daily insulin titration instructions.</description>
    <arm_group_label>Voice Assistant Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Type 2 Diabetes with most recent A1c at least 8% within the past year&#xD;
&#xD;
          -  Patients clinically indicated to be taking daily long-acting insulin&#xD;
&#xD;
          -  Patients currently taking long-acting insulin but necessitating active dose&#xD;
             adjustments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on short-acting or intermediate-acting insulin&#xD;
&#xD;
          -  Patients who do not speak English&#xD;
&#xD;
          -  Patients who do not own a smart phone&#xD;
&#xD;
          -  Patients who do not have stable wireless internet connection at home&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Schulman, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashwin Nayak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharif Vakili, MD, MS, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Team</last_name>
    <phone>650-308-8062</phone>
    <email>mivatrial@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Kevin Schulman</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Voice Assistant</keyword>
  <keyword>Medication Management</keyword>
  <keyword>Insulin Management</keyword>
  <keyword>Smart Speaker</keyword>
  <keyword>AI</keyword>
  <keyword>Artificial Intelligence</keyword>
  <keyword>Autonomous Prescriptions</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

